← Leaderboards
Andre Rosowsky
Dana-Farber Cancer Institute
$3,858,339
Attributed
$3,858,339
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,858,339 · 2
By mechanism
R01$3,858,339 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionDihydrofolate ReductaseFolate AntagonistEnzyme InhibitorsAidsChemical SynthesisCryptosporidiumDiaminopyrimidineDrug Adverse EffectDrug MetabolismDrug ResistancePneumocystis CariniiPolyglutamatesProdrugsToxoplasma GondiiNeoplasm /Cancer PharmacologyOpportunistic InfectionsAntineoplasticsPharmacokineticsAminopterinHomocysteineLigandsMembrane Transport ProteinsMethotrexate Analog
Grant awards (8)
Lipophilic antifolates and AIDS opportunistic infections$511,853
R01 · FY2004 · AI
NOVEL APPROACHES TO ANTIFOLATE CHEMOTHERAPY$551,261
R01 · FY2003 · CA
Lipophilic antifolates and AIDS opportunistic infections$496,945
R01 · FY2003 · AI
NOVEL APPROACHES TO ANTIFOLATE CHEMOTHERAPY$535,856
R01 · FY2002 · CA
Lipophilic antifolates and AIDS opportunistic infections$483,292
R01 · FY2002 · AI
NOVEL APPROACHES TO ANTIFOLATE CHEMOTHERAPY$521,769
R01 · FY2001 · CA
NOVEL APPROACHES TO ANTIFOLATE CHEMOTHERAPY$466,920
R01 · FY2000 · CA
LIPOPHILIC ANTIFOLATES AND AIDS OPPORTUNISTIC INFECTIONS$290,443
R01 · FY2000 · AI